SA 401
Alternative Names: SA-401Latest Information Update: 19 Oct 2022
At a glance
- Originator Sian Wuhan Medical Technology
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 08 Sep 2022 Preclinical trials in Non-small cell lung cancer in China (Parenteral) (Sian Wuhan Medical Technology pipeline, September 2022)
- 08 Sep 2022 Preclinical trials in Ovarian cancer in China (Parenteral) (Sian Wuhan Medical Technology pipeline, September 2022)
- 08 Sep 2022 Sian Wuhan Medical Technology plans investigator initiated trial for ovarian cancer and non-small cell lung cancer by 2024 (Sian Wuhan Medical Technology pipeline, September 2022)